SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its price target lowered by analysts at Chardan Capital from $25.00 to $20.00. They now have a "buy" rating on the stock.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
SAB BIO Reports Full Year 2024 Operating and Financial Results
SAB BIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
SAB BIO to Participate in Upcoming Investor Conferences